Obesity Clinical Trial
— PREVAIL-POfficial title:
Prescribed Exercise to Reduce Recidivism After Weight Loss Pilot (PREVAIL-P)
Verified date | June 2021 |
Source | East Carolina University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Prescribed Exercise to Reduce Recidivism After Weight Loss Pilot (PREVAIL-P) study will evaluate the effect of aerobic exercise training amount on weight maintenance following clinically significant weight loss.
Status | Completed |
Enrollment | 39 |
Est. completion date | March 15, 2020 |
Est. primary completion date | March 15, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Men and women 18-65 years of age (postmenopausal females permitted) - Body mass index: 25-39.9 kg/m2 at enrollment - The capability and willingness to provide written informed consent - Willingness to accept group assignment from randomization - No resistance training and no structured aerobic exercise for > 20 minutes per day, 3+ days per week, for the last 6 months - Conditions that are contraindicated for exercise training Exclusion Criteria: - Resting blood pressure > 180 mm Hg systolic and/or >100 mm Hg diastolic (individuals on blood pressure medications meeting the blood pressure criteria are eligible) - Diagnosis of type 1 or 2 diabetes, and/or fasting glucose >125 mg/dL - Medication for the treatment of type 1 or type 2 diabetes - Bariatric surgery including gastric banding or bypass (potential effects on energy intake) - Factors that may limit adherence to intervention or affect conduct of the trial - Unable or unwilling to communicate with staff - Failure to complete run-in or baseline testing - Hospitalization for depression or severe mental illness in the last 6 months - Not physically capable of performing the exercise required of the study protocol - Consuming more than 14 alcoholic beverages per week - Plan to be away from the Pitt County area more than 3 weeks in the next 3 months - Lack support from a primary health care provider or family members - Significant weight loss in the past year (> 20 pounds) or are currently using weight loss medications. - Current diagnosis of schizophrenia, other psychotic disorders, or bipolar disorder - Other temporary intervening event, such as sick spouse, or bereavement - Other medical, psychiatric, or behavioral limitations that may interfere with study participation or the ability to follow the intervention protocol - Underlying diseases or conditions likely to limit lifespan and/or affect the safety of the intervention - Cancer requiring treatment in the past 5 years with anything but excellent prognosis - Self-reported HIV, tuberculosis, Hepatitis B, or Hepatitis C - History or evidence of serious arrhythmias, cardiomyopathy, congestive heart failure, aortic aneurism, myocardial infarction or heart transplantation - Renal disease: urine protein > 100 mg/dl, serum creatinine = 1.5 mg/dl or currently receiving dialysis. - Auto-immune diseases (such as Lupus, Multiple Sclerosis, Graves' disease, or Rheumatoid arthritis) - Chronic obstructive lung disease, peripheral vascular disease or angina that limits ability to follow exercise protocol - History of stroke or transient ischemic attack - History of vascular aneurysms - History of bleeding disorders - Pregnancy or plans to become pregnant - Any other medical condition or disease that is life threatening or that can interfere with or be aggravated by exercise. - Do not own smartphone for MyFitnessPal and Centrepoint Apps. - Lack of an internet connection |
Country | Name | City | State |
---|---|---|---|
United States | East Carolina University | Greenville | North Carolina |
Lead Sponsor | Collaborator |
---|---|
East Carolina University | Pennington Biomedical Research Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in weight | Weight will measured in a hospital gown | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in cardiorespiratory fitness | Fitness will be measured using a modified Balke protocol on a treadmill. Participants will walk at an initial speed of 2.0 mph with 0% grade for the first 3 minutes after which the treadmill speed will increase to 3.0 mph for the next 3 minutes. The treadmill grade will be increased by 2.5% every 3 minutes until volitional exhaustion. Respiratory gases (VO2, CO2) and ventilation will be measured continuously using a True Max 2400 Metabolic Measurement Cart. | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in body composition | Dual-energy X-ray absorptiometry will be used to measure changes in fat and lean mass. | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in waist circumference | Waist circumference will be measured at the natural waist (midway between the inferior border of the rib cage and the superior aspect of the iliac crest) with a gulick tape measure. Both landmarks (the inferior border of the ribcage and the superior aspect of the iliac crest) will be marked and the distance will be measured to determine the appropriate measurement site. Staff will confirm that: 1) the measurement tape remains horizontal; 2) the tape touches the entire circumference of the participant; 3) abdominal tissue is not compressed; 3) the tape measure is not within abdominal folds; 4) the measurement is taken at the end of normal respiration. The measurement will be repeated an additional time, and the reported value will be the average of these measurements. Both measurements must be within 0.5 cm to be considered acceptable for data purposes. | Baseline, 10 weeks and 28 weeks | |
Secondary | Changes in physical activity levels | Participants will wear an ActivPal accelerometer for seven consecutive days, 24-hrs/day. The amount of time spent sitting and standing and steps will be calculated | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in dietary composition | Food Frequency Questionnaire (FFQ) contains approximately 105 items grouped by categories and is completed for both frequency of consumption as well as portion size selections by the individual. The questionnaire, upon completion, provides estimated daily intake values for selected nutrients (kilocalories, macronutrients, and micronutrients) and provides information on food group servings. | Baseline, 10 weeks and 28 weeks | |
Secondary | Changes in blood lipids concentrations | Low density lipoproteins, high density lipoproteins, total cholesterol, and triglycerides will be measured from baseline and 24 weeks from blood samples by Labcorp Inc. | Baseline, 10 weeks and 28 weeks | |
Secondary | Changes in lipoprotien class/size | Full lipoprotein class/size analysis will be preformed by Liposcience | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in systemic inflammation | High sensitivity c-reactive protein will be measured | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in insulin sensitivity | Insulin sensitivity will be measured using an intravenous glucose tolerance test | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in arterial stiffness | Arterial stiffness will be measured using pulse wave velocity | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in blood pressure | Brachial and aortic blood pressure will be measured using a sphygmocor XCEL | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in quality of life: SF-36 | Quality of life (QOL) will be measured by the short form health survey (SF-36). SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS). | Baseline, 10 weeks and 28 weeks | |
Secondary | Change in resting metabolic rate | Resting metabolic rate will be measured using indirect calorimetry | Baseline, 10 weeks and 28 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |